Influence of local reference populations on upper limits of normal for serum alanine aminotransferase levels

Archives of Internal Medicine

Volumn 168, Issue 6, 2008, Pages 663-666

  Neuschwander Tetri, Brent A ^a,b   Ünalp, Aynur ^a   Creer, Michael H ^a  

^a Nonalcoholic Steatohepatitis Clinical Research Network

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; CHRONIC LIVER DISEASE; CLINICAL TRIAL; DIAGNOSTIC VALUE; FEMALE; HUMAN; INTERMETHOD COMPARISON; LABORATORY DIAGNOSIS; LETTER; MALE; MULTICENTER STUDY; NONALCOHOLIC FATTY LIVER; OBESITY; POPULATION RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; REFERENCE VALUE; RISK BENEFIT ANALYSIS; RISK FACTOR; SCREENING TEST; VALIDATION STUDY;

ALANINE TRANSAMINASE; CHRONIC DISEASE; HUMANS; LIVER DISEASES; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS;

EID: 41549129499     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2007.131     Document Type: Letter

References (9)

1. Canalias F, Camprubi S, Sanchez M, Gella FJ. Metrological traceability of values for catalytic concentration of enzymes assigned to a calibration material. Clin Chem Lab Med. 2006;44(3):333-339.
2. PetitClerc C, Wilding P. The theory of reference values: part 2, selection of individuals for the production of reference values. J Clin Chem Clin Biochem. 1984;22(2):203-208.
3. Prati D, Taioli E, Zanella A, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137(1):1-9.
4. Kaplan MM. Alanine aminotransferase levels: what's normal? Ann Intern Med. 2002;137(1):49-51.
5. Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and diagnostic implications of the proposed new normal range for serum ALT in obese women. Hepatology. 2005;42(3):650-656.
6. Chang Y, Ryu S, Sung E, Jang Y. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem. 2007;53(4):686-692.
7. Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ. 2004;328(7446):983.
8. Lavine JE, Schwimmer JB. Clinical Research Network launches TONIC trial for treatment of nonalcoholic fatty liver disease in children. J Pediatr Gastroenterol Nutr. 2006;42(2):129-130.
9. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40(6):1387-1395.